Glaukos (GKOS) Stock Forecast & Price Target

Glaukos Corporation has shown significant growth in its glaucoma segment, with 3Q25 revenues reaching $110 million, surpassing consensus expectations and marking a 45% increase year-over-year. The domestic glaucoma revenue, which totaled $81 million, also exceeded estimates, reflecting a robust 57% growth, while international revenues contributed positively with a 17% increase on a constant currency basis. Additionally, the strong adoption prospects for the Epioxa therapy, indicated by rising utilization rates expected through 2028, further supports the company's competitive positioning and future revenues in the ophthalmic market.

The excerpts indicate a negative outlook for Glaukos Corp due to multiple factors impacting its revenue growth. Sales in the corneal health sector have slowed, with compounded annual growth rates (CAGRs) dropping significantly, indicating potential struggles in this segment as well as a decline in legacy surgical glaucoma products, which fell by 4.7% to $40.8 million. Furthermore, anticipated decreases in Epioxa volumes and potential challenges from a competitive market, slow adoption of new products like iDose and infinite, and changes in the reimbursement landscape further contribute to the pervasive concerns about the company's financial performance moving forward.